SARS-CoV-2 Omicron Variant Neutralization after mRNA-1273 Booster Vaccination is a research paper published in New England Journal of Medicine (2022). On theSindex it has a DataRank of 0.897. It has been cited 394 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.897
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority
Grant: 75A50120C00034
HIV Vaccine Trials Network (HVTN) Leadership and Operations Center
Grant: UM1 AI 68614HVTN
NIAID to Statistics and Data Management Center
Grant: UM1 AI 68635
NIAID to the HVTN Laboratory Center
Grant: UM1 AI 68618
NIAID to the Prevention Trials Network Leadership and Operations Center
Grant: UM1 AI 68619
NIAID to AIDS Clinical Trials Group Leadership and Operations Center
Grant: UM1 AI 68636
NIAID to Infectious Diseases Clinical Research Consortium leadership group 5
Grant: UM1 AI148684-03
National Institutes of Health
Grant: NIH 75N93019C00050 (DCM, XS)
National Institutes of Health
Grant: NIH U19 AI142790 (BK)
National Institutes of Health
Grant: NIH UM1 AI148689 (KL)
National Institutes of Health
Grant: NIH UM1AI148575 (RLA)
National Institutes of Health
Grant: NIH UM1AI148684 (LG)
NIAID NIH HHS
Grant: UM1 AI068614
NIAID NIH HHS
Grant: UM1 AI068635
NIAID NIH HHS
Grant: R37 AI150590
NIAID NIH HHS
Grant: 75N93019C00050
NIAID NIH HHS
Grant: UM1 AI068617
NIAID NIH HHS
Grant: U19 AI142790
NIAID NIH HHS
Grant: UM1 AI068636
NIAID NIH HHS
Grant: UM1 AI148575
NIAID NIH HHS
Grant: UM1 AI068619
NIAID NIH HHS
Grant: UM1 AI148689
NIAID NIH HHS
Grant: P01 AI158571
NIAID NIH HHS
Grant: UM1 AI068618
NIAID NIH HHS
Grant: UM1 AI069412
NIAID NIH HHS
Grant: UM1 AI148684
National Institutes of Health
Grant: 3UM1AI148689-03S5
Implementing Vaccine and Treatment Evaluation Unit (VTEU) Clinical Site
National Institutes of Health
Grant: 3UM1AI068635-17S4
CoVPN 3001 - A Phase 3, Randomized, Stratified, Observer-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1273 SARS-CoV-2 Vaccine in Adults.
National Institutes of Health
Grant: 5U19AI142790-04
Consortium for Immunotherapeutics against Emerging Viral Threats
National Institutes of Health
Grant: 5UM1AI148575-06
Vaccine and Treatment Evaluation Units (VTEU)
National Institutes of Health
Grant: 3UM1AI148684-03S1
Leadership Group for the Infectious Diseases Clinical Research Consortium (IDCRCLG)
National Institutes of Health
Grant: 3UM1AI068636-19SC
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
National Institutes of Health
Grant: 3UM1AI068618-16S1
HVTN 405/HPTN 1901 (CoVPN) Characterizing SARS-CoV-2-specific Immunity in Convalescent Individuals: LC 3
National Institutes of Health
Grant: 5UM1AI068619-09
LOC: HIV Prevention Trials Network
Moderna, Inc.
Intramural Research Program of the Vaccine Research Center, NIAID, NIH
FWCI
37.14
Citation Percentile
1.0%
Citation Trend
Fields of Study
Keywords
Additional file 1 of A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network
Additional file 1 of A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network
Additional file 2 of A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network
Additional file 2 of A multinational, phase 2, randomised, adaptive protocol to evaluate immunogenicity and reactogenicity of different COVID-19 vaccines in adults ≥75 already vaccinated against SARS-CoV-2 (EU-COVAT-1-AGED): a trial conducted within the VACCELERATE network
Additional file 1 of Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination
Additional file 1 of Correlates of protection and determinants of SARS-CoV-2 breakthrough infections 1 year after third dose vaccination
Additional file 2 of Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern
Additional file 1 of Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern
Additional file 2 of Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern
Additional file 1 of Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern